Integrated Bioinformatics and Pharmacogenomic Profiling of a Gene Panel in Diabetes Mellitus Treatment Response
de Oliveira Andrade, L. J.; Matos de Oliveira, G. C.; Leahy Neto, J. M.; de Mattos Salles, O. J.; Vinhaes Bittencourt, A. M.; Matos de Oliveira, L.
Show abstract
BackgroundPharmacogenomic variability significantly influences diabetes mellitus (DM) treatment outcomes, yet systematic integration of multi-gene panels combining bioinformatics-driven discovery with cross-database validation remains limited across diverse populations. ObjectiveTo develop and validate a comprehensive 20-gene pharmacogenomic panel for predicting drug metabolism variability and treatment response in DM through integrated bioinformatics approaches. MethodsSystematic literature mining identified candidate genes through PubMed searches (2015-2025). Multi-criteria decision analysis prioritized genes across insulin secretion, insulin sensitivity, glucose metabolism, and drug metabolism pathways. Analyses included Gene Ontology enrichment, KEGG pathway mapping, STRING protein-protein interaction networks, variant annotation (dbSNP/ClinVar/PharmGKB), pathogenicity prediction (CADD/PolyPhen-2/SIFT), GTEx tissue-specific expression profiling, and DrugBank drug-gene interaction mapping. Cross-database validation assessed concordance across PharmGKB, DrugBank, GWAS Catalog, and PhKB. ResultsThe panel encompassed 20 genes distributed across 14 chromosomes. Network analysis revealed 87 edges with clustering coefficient 0.653, identifying 5 hub genes. Variant annotation catalogued 3,847 polymorphisms, including 247 pathogenic/likely pathogenic variants. Population analyses demonstrated 3.8-fold inter-ethnic allele frequency variations. PharmGKB integration identified 127 gene-drug pairs (23 Level 1A associations). Cross-database concordance achieved 87.3% (PharmGKB-DrugBank), 82.6% (GWAS Catalog), and 79.4% (PhKB). DrugBank identified 89 antidiabetic drug-gene interactions. Novel associations from recent publications demonstrated statistical significance in cohorts exceeding 2,000 patients. ConclusionsThis integrated framework provides validated foundations for precision diabetes therapeutics. Prospective clinical validation remains essential to translate computational discoveries into actionable decision-support tools optimizing therapeutic outcomes.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish-Norwegian cohort study 92%
- A Microbiome-targeting Fiber-enriched Nutritional Formula is Well Tolerated and Improves Quality of Life and Hemoglobin A1c in Type 2 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Trial 92%
- Integrated miRNA_mRNA Analysis Reveals Dysregulated Regulatory Networks in Visceral Adipose Tissue Linked to Obesity and Type 2 Diabetes 92%
Similar papers in this journal
- Acute pharmacodynamic responses to sitagliptin: Drug-induced increase in early insulin secretion in oral glucose tolerance test. 93%
- A Framework to Quantify Disparities in Pharmacogenomic Treatment Concordance and Drug Response Outcomes 91%
- A long-acting GDF15 analog causes robust, sustained weight loss and reduction of food intake in an obese non-human primate model 90%
Similar papers in this journal
- Population Pharmacokinetic Analysis of Dexmedetomidine in Children using Real-World-Data Obtained from Electronic Health Records and Remnant Clinic Samples 91%
- People exposed to proton pump inhibitors shortly preceding COVID-19 diagnosis are not at an increased risk of subsequent hospitalizations and mortality: a nation-wide matched cohort study 90%
- Endothelial-protective effects of a G-protein-biased sphingosine-1 phosphate receptor-1 agonist, SAR247799, in type-2 diabetes rats and a randomized placebo-controlled patient trial. 90%
Similar papers in this journal
- Use of evidence-based cardiovascular preventive therapies in type 2 diabetes patients with established or high risk of atherosclerotic cardiovascular disease in China: A retrospective cohort study 92%
- Metabolic Drivers of Dysglycemia in Pregnancy: Ethnic-Specific GWAS of 146 Metabolites and 1-Sample Mendelian Randomisation Analyses in a UK Multi-Ethnic Birth Cohort 91%
- Observational assessments of the relationship of dietary and pharmacological treatment on continuous measures of dysglycemia over 24 hours in women with gestational diabetes 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.